Potassium [[N,N'-ethylenebis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']ferrate(1-)

Endpoint summary

Description of key information

LD50 (oral, rat) exceeds 2000 mg/kg bw

LD50 (dermal, rat) exceeds 2000 mg/kg bw (read across with ETD-FeNa)

LC50 (rat, 4h) exceeded 2.75 +/- 0.19 mg/L, the maximum attainable concentration (read across with EDTA-FeNa).

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

30 September - 21 October 2014

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: The study has been performed according to OECD and/or EC guidelines and according to GLP principles.

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)

Deviations:

no

Qualifier:

according to guideline

Guideline:

EPA OPPTS 870.1100 (Acute Oral Toxicity)

Deviations:

no

Qualifier:

according to guideline

Guideline:

other: Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF), 12 Nohsan, Notification No 8147, April 2011, including the most recent partial revisions.

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

acute toxic class method

Limit test:

no

Species:

rat

Strain:

other: Wistar (Han)

Sex:

female

Details on test animals or test system and environmental conditions:

- Source: Charles River Deutschland, Sulzfeld, Germany.
- Age at study initiation: Young adult animals (approx. 8-10 weeks old)
- Weight at study initiation: Body weight variation was within +/- 20% of the sex mean.
- Fasting period before study: Animals were deprived of food overnight prior to dosing and until 3-4 hours after administration of the test substance. Water was available ad libitum.
- Housing: Group housing of 3 animals per cage in labeled Macrolon cages
- Diet: Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
- Water: Free access to tap water.
- Acclimation period: At least 5 days

Environmental controls for the animal room were set to maintain 18 to 24°C, a relative humidity of 40 to 70%, approximately 15 room air changes/hour, and a 12-hour light/12-hour dark cycle. Any variations to these conditions were maintained in the raw data and had no effect on the outcome of the study.

IN-LIFE DATES: From: 30 September - 21 October 2014

Route of administration:

oral: gavage

Vehicle:

water

Details on oral exposure:

GAVAGE METHOD: plastic feeding tubes.
Frequency: single dosage, on Day 1.

VEHICLE
- Justification for choice of vehicle: The vehicle was selected based on trial formulations performed at WIL Research Europe and on test substance data supplied by the sponsor.

MAXIMUM DOSE VOLUME APPLIED: 1927 mg/kg body weight

DOSAGE PREPARATION: The formulations (w/w) were prepared within 4 hours prior to dosing. Homogeneity was accomplished to a visually acceptable level.

Doses:

1927 mg/kg body weight

No. of animals per sex per dose:

6 (2 groups of three females in a stepwise manner)

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Mortality/Viability: Twice daily.
Body weights: Days 1 (pre-administration), 8 and 15.
Clinical signs: At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15.
- Necropsy of survivors performed: At the end of the observation period, all animals were sacrificed by oxygen/carbon dioxide procedure and subjected to necropsy. Descriptions of all internal macroscopic abnormalities were recorded.
- Other examinations performed: none.

Statistics:

No statistical analysis was performed (The method used is not intended to allow the calculation of a precise LD50 value).

Sex:

female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

No mortality occurred.

Clinical signs:

other: Hunched posture and piloerection were noted for all animals between Days 1 and 4. Additionally, three animals also showed diarrhoea on Day 3.

Gross pathology:

No treatment related abnormalities were found at macroscopic post mortem examination of the animals. A diaphragmatic hernia of the left median liver lobe was found in one animal. Since this is occasionally seen among rats of this age and strain and it was found in one animal only, this was considered not toxicologically significant.

Interpretation of results:

not classified

Remarks:

Migrated information Criteria used for interpretation of results: EU

Conclusions:

The oral LD50 value of EDTA-FeK in Wistar rats was established to exceed 1927 mg/kg body weight. Since the difference with the intended dose level was less than 4%, it was considered that the obtained results would be comparable to those that would be obtained at 2000 mg/kg bw. Therefore it was considered that the oral LD50 value of EDTA-FeK exceeded 2000 mg/kg body weight. Based on this consideration and according to the OECD 423 test guideline, the LD50 cut-off value was considered to exceed 5000 mg/kg body weight. Based on these results, EDTA-FeK does not have to be classified and has no obligatory labelling requirement for acute oral toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2011) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures (including all amendments).

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Quality of whole database:

One study available for EDTA-FeK, LD50 > 2000 mg/kg. Several studies available for EDTA-FeNa. LD50 > 2000 mg/kg and perhaps even > 5000 mg/kg bw.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Quality of whole database:

Two studies available for EDTA-FeNa (see read across document in section 13); 4-h LC50 > 2.75 mg/L (maximum attainable concentration).

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Quality of whole database:

Two studies available for EDTA-FeNa. LD50 > 2000 mg/kg and perhaps even > 5000 mg/kg bw.

Additional information

The key study shows very low acute oral toxicity via the oral route of exposure. EDTA-FeNa also shows very low acute oral toxicity via the 'normal' routes of exposure, viz. oral, dermal and inhalation. No mortalities occured in the key studies. The LD50/LC50s found in the key studies are supported by values from literature.

Via a non-physiological route of human exposure, viz intraperitoneal injection, the LD50 for EDTA-FeNa in mice was lower, viz. 160 mg/kg bw.

Justification for selection of acute toxicity – oral endpoint

Key study

Justification for classification or non-classification

The key study shows that LD50 (oral, rat) exceeds 2000 mg/kg bw. Read across with EDTA-FeNa (see also section 13) shows that LD50 (dermal, rat) exceeds 2000 mg/kg bw and LC50 (rat, 4h) exceeded 2.75 +/- 0.19 mg/L, the maximum attainable concentration. Therefore classification for acute toxicity is not warranted.